ClinicalTrials.gg
CompletedNCT01744288Updated Apr 24, 2014

Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets

A Phase 1 interventional study of Ticagrelor and Clopidogrel in Inhibition on Platelet Aggregation, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-24.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Study to see if platelet transfusion stop or lessen the effect of the drug on platelets

Read the detailed description

A open label, randomized, crossover and potential parallel, single dose study of ticagrelor 180 mg and acetylsalicylic acid (ASA) in healthy volunteers followed by autologous in vivo platelet transfusion to determine the effects of platelet supplementation on the reversibility of platelet inhibition

02

Conditions studied

  • Inhibition on Platelet Aggregation

Keywords

  • Phase 1 Safety ,
  • pharmacodynamic,
  • Ticagrelor,
  • Clopidogrel,
  • Platelets
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures
  • Healthy male and/or female volunteers aged 18 to 50 years, inclusive, with suitable veins for cannulation or repeated venipuncture. (Healthy as determined by medical history and physical examination, laboratory parameters, (ECG) perform
  • Have a (BMI) between 18 and 35 kg/m2 (inclusive) and weigh at least 50 kg and no more than 120 kg

Exclusion criteria

Exclusion Criteria:

  • ADP induced aggregation \<60% prior to platelet apheresis
  • History of peptic ulcer disease Healthy volunteers with a propensity to bleed (eg, due to recent trauma, recent surgery, active or recent gastrointestinal bleeding or moderate hepatic impairment)
  • Any illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the product
  • Current smokers, those who have smoked or used nicotine products within the previous 3 months and those who tested positive for cotinine at screening or at admission to the study center
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    1

    Ticagrelor with Platelet transfusion

    Drug: Ticagrelor · Drug: ASA

  • Experimental
    2

    Ticagrelor without Platelet transfusion

    Drug: Ticagrelor · Drug: ASA

  • Active comparator
    3

    Clopidogrel with Platelet transfusion

    Drug: Clopidogrel · Drug: ASA

  • Active comparator
    4

    Clopidogrel without Platelet transfusion

    Drug: Clopidogrel · Drug: ASA

Interventions

  • Oral single loading dose 180ng

  • Oral single loading dose 600mg

  • DrugASA

    81mg once daily from day -2 up to platelet transfusion

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics in terms of percent of inhibition of adenosine phosphatase (ADP)-induced platelet aggregation assessed by light transmission aggregometry (LTA) after loading dose of Ticagrelor

    Time frame: Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h

Secondary outcomes

  1. Pharmacodynamics in terms of platelet reactivity as measured by P2Y12 Reaction Units (PRU) using VerifyNow™ after loading dose of Ticagrelor

    Time frame: Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h

  2. Pharmacodynamics in terms of platelet reactivity as measured by P2Y12 Reaction Units (PRU) using VerifyNow™ after loading dose of Clopidogrel

    Time frame: Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h

  3. Pharmacodynamics in terms of percent of inhibition of adenosine phosphatase (ADP)-induced platelet aggregation assessed by light transmission aggregometry (LTA) after loading dose of Clopidogrel

    Time frame: Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h

  4. Safety profile in terms of adverse events, blood pressure, pulse, temperature, ECG (Electrocardiogram), physical examination, and safety laboratory variables

    Time frame: up to 9 weeks

07

Study locations

1 site
  • Research Site
    Overland Park, Kansas, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2012
First posted
Dec 6, 2012
Start
Dec 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Last update
Apr 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01744288
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 6, 2012
Start date
Dec 2012
Primary completion
Apr 2014
Completion
Apr 2014
Last update
Apr 24, 2014

Study contacts

Glenn Carlson, MD
study chair · AstraZeneca Wilmington US
Phil Leese, MD
principal investigator · Overland Park US, Quintiles, Inc
Judi Hsia, MD
study director · Wilmington, US AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion